PURPOSE: The event-free survival (EFS) of children with standard-risk acute lymphoblastic leukemia (SR-ALL) is now more than 80%. However, prognosis after relapse continues to be poor. We examined postrelapse outcomes of children initially treated on the Children's Cancer Group CCG-1952 study. PATIENTS AND METHODS: We evaluated outcomes after bone marrow (BM) relapse and isolated extramedullary (EM) relapse for 347 patients with SR-ALL (WBC < 50,000/microL; age, 1 to 9 years). The prognostic significance of several factors for EFS after relapse (EFS2) was assessed by Cox regression analysis. Stem-cell transplant (SCT) was compared with chemotherapy as salvage treatment. RESULTS: The mean +/- SE times to isolated central nervous system relapse, BM relapse, and isolated testicular relapse were 23 +/- 1 months (range, 1 to 88 months), 36 +/- 1 months (range, 2 to 79 months), and 40 +/- 2 months (range, 16 to 64 months), respectively. The estimated percent +/- SE 3-year EFS2 and overall survival rates after BM relapse were 37% +/- 4% and 46% +/- 4%, respectively, and rates after isolated EM relapse were 57% +/- 5% and 71% +/- 5%, respectively. By multivariate analysis, we found the duration of first remission to be the most significant predictor of EFS2 for either BM relapse or isolated EM relapse. Outcome was equivalent with SCT or chemotherapy after early or late relapse of SR-ALL at any site. CONCLUSION:Duration of first remission remains the most significant predictor of outcome after either BM or isolated EM relapse of SR-ALL. Prognosis after early BM relapse remains poor and is not improved with SCT in this cohort.
RCT Entities:
PURPOSE: The event-free survival (EFS) of children with standard-risk acute lymphoblastic leukemia (SR-ALL) is now more than 80%. However, prognosis after relapse continues to be poor. We examined postrelapse outcomes of children initially treated on the Children's Cancer Group CCG-1952 study. PATIENTS AND METHODS: We evaluated outcomes after bone marrow (BM) relapse and isolated extramedullary (EM) relapse for 347 patients with SR-ALL (WBC < 50,000/microL; age, 1 to 9 years). The prognostic significance of several factors for EFS after relapse (EFS2) was assessed by Cox regression analysis. Stem-cell transplant (SCT) was compared with chemotherapy as salvage treatment. RESULTS: The mean +/- SE times to isolated central nervous system relapse, BM relapse, and isolated testicular relapse were 23 +/- 1 months (range, 1 to 88 months), 36 +/- 1 months (range, 2 to 79 months), and 40 +/- 2 months (range, 16 to 64 months), respectively. The estimated percent +/- SE 3-year EFS2 and overall survival rates after BM relapse were 37% +/- 4% and 46% +/- 4%, respectively, and rates after isolated EM relapse were 57% +/- 5% and 71% +/- 5%, respectively. By multivariate analysis, we found the duration of first remission to be the most significant predictor of EFS2 for either BM relapse or isolated EM relapse. Outcome was equivalent with SCT or chemotherapy after early or late relapse of SR-ALL at any site. CONCLUSION: Duration of first remission remains the most significant predictor of outcome after either BM or isolated EM relapse of SR-ALL. Prognosis after early BM relapse remains poor and is not improved with SCT in this cohort.
Authors: Blake S Moses; Rebecca Evans; William L Slone; Debbie Piktel; Ivan Martinez; Michael D Craig; Laura F Gibson Journal: Mol Cancer Res Date: 2016-06-29 Impact factor: 5.852
Authors: Laura E Hogan; Julia A Meyer; Jun Yang; Jinhua Wang; Nicholas Wong; Wenjian Yang; Gregory Condos; Stephen P Hunger; Elizabeth Raetz; Richard Saffery; Mary V Relling; Deepa Bhojwani; Debra J Morrison; William L Carroll Journal: Blood Date: 2011-09-14 Impact factor: 22.113
Authors: Elena J Ladas; David J Kroll; Nicholas H Oberlies; Bin Cheng; Deborah H Ndao; Susan R Rheingold; Kara M Kelly Journal: Cancer Date: 2010-01-15 Impact factor: 6.860
Authors: Yi Zhou; Rebecca Slack; Jeffrey L Jorgensen; Sa A Wang; Gabriela Rondon; Marcos de Lima; Elizabeth Shpall; Uday Popat; Stefan Ciurea; Amin Alousi; Muzaffar Qazilbash; Chitra Hosing; Susan O'Brien; Deborah Thomas; Hagop Kantarjian; L Jeffrey Medeiros; Richard E Champlin; Partow Kebriaei Journal: Clin Lymphoma Myeloma Leuk Date: 2014-01-15
Authors: S Krishnan; R Wade; A V Moorman; C Mitchell; S E Kinsey; T O B Eden; C Parker; A Vora; S Richards; V Saha Journal: Leukemia Date: 2009-12-17 Impact factor: 11.528